CASE REPORT

Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy

Asako Onda, Shinji Miyagawa, Naoko Takahashi, Mina Gochi, Masamichi Takagi, Ichizo Nishino, Shigeaki Suzuki, Chizuko Oishi and Hiroshi Yaguchi

Abstract:
A 73-year-old man developed diplopia after the administration of pembrolizumab for lung adenocarcinoma. He had ptosis and external ophthalmoplegia without general muscle weakness. Serum CK levels were elevated. Although autoantibodies to acetylcholine receptor and muscle-specific kinase, the edrophonium test, and the repetitive nerve stimulation test were all negative, anti-titin autoantibody was positive, leading to the diagnosis of myasthenia gravis (MG). Muscle pathology showed necrotizing myopathy with tubular aggregates. Unlike previously reported cases of pembrolizumab-associated MG, the present case showed ocular MG. This is the first case of pembrolizumab-associated MG with anti-titin antibody, as well as the first case with tubular aggregates.

Key words: pembrolizumab, ocular myasthenia gravis, anti-titin antibody, necrotizing myopathy, tubular aggregates

Background
Pembrolizumab is an anti-programmed cell death 1 (PD-1) monoclonal antibody that is used for therapy against lung cancer. Increasing evidence suggests that it can cause myasthenia gravis (MG) and necrotizing myopathy, although the detailed clinicopathological features are still unclear (1).

Case Report
A 73-year-old man with hypertension and mitral valve regurgitation with no relevant family history of neuromuscular disorders was found to have a lung nodule on a regular medical checkup in 2016. Subsequently, a diagnosis of lung adenocarcinoma with brain and bone metastases was made by pulmonologists. The tumor proportion score of the programmed cell death-ligand 1 (PD-L1) expression was 85%, so he was started on pembrolizumab in July 2017 (day 1).

On day 23, he was found to have diplopia, and his CK level had increased from 55 to 600 U/L. He was admitted to our hospital on day 30 with stable vital signs. On a physical examination, he had diplopia and ptosis in the left eye with daily fluctuation. He had no easy fatigability or weakness in the limbs and trunk. On laboratory testing, his CK level was 7,311 U/L, aldolase 16.5 IU/L, AST 172 U/L, ALT 74 U/L, LDH 631 U/L, creatinine 1.17 mg/dL, CRP 0.68 mg/dL, ESR 34 mm/h, and D-dimer 1.4 μg/mL. His thyroid function was within the normal range (TSH 1.75 μIU/mL, FT3 2.61 pg/mL, FT4 1.05 ng/dL). Rheumatoid factor, antinuclear antibody, anti-double stranded DNA (dsDNA) antibody, anti-ribonucleoprotein (RNP) antibody, anti-histidyl transfer RNA synthetase (Jo-1) antibody, anti-aminooacyl transfer RNA synthetase (ARS) antibody, anti-mitochondrial M2 (M2) antibody, anti-signal recognition particle (SRP) antibody, and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGR) antibody were all negative. Anti-acetylcholine receptor (AChR) antibody, anti-
The left biceps brachii showed scattered necrotic and regenerative changes. Magnetic resonance imaging of the thigh muscles showed no evidence of myopathy. A muscle biopsy from the biceps muscle showed a good ejection fraction (70%) and no myocarditis. In the present case, anti-AChR antibody was negative, but anti-titin antibody was positive. Accordingly, the diagnosis of MG was made. The Quantitative MG score was 6 points (ptosis and diplopia: 3 and 3 points, respectively). The patient was given an ascending-dose regimen of prednisolone that increased by 5 mg every 5 days to a total of 20 mg. He initially had exacerbation of ptosis and ophthalmoplegia with diplopia. The CK level showed a trend toward reduction, but it remained high. Therefore, steroid pulse therapy (methylprednisolone 1 g/day 3 times) was given. The CK level then normalized promptly, and his symptoms improved gradually. All abnormal neurological findings disappeared four months after the start of steroid therapy (Fig. 2).

### Discussion

Immunotherapy is a recently established treatment method for lung cancer. Representative agents include antibodies targeting immune checkpoints, such as PD-1, PD-L1, and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4). Pembrolizumab and nivolumab are anti-PD-1 monoclonal antibodies. These agents connect with PD-1 expressed on activated T cells and exert their anticancer activity by eliminating the suppression of activated T cells (1). These immune checkpoint inhibitors are reported to cause immune-related adverse events (irAEs), including MG and myopathy (2), although the pathomechanism is still unclear.

Although the previously reported cases of anti-PD-1 monoclonal antibody-associated MG (anti-PD-1-associated MG) showed a relatively severe generalized type (3), the present case showed ocular MG without generalized symptoms. There have been four cases of anti-PD-1-associated MG that presented with the ocular type (Table) (3-5). Even if patients show ocular MG, there is the possibility of general inflammation, such as the elevation of the serum CK level and myopathy on electromyography and a muscle biopsy.

There are some cases of co-existing anti-striated muscle antibody (anti-titin, anti-ryanodine, anti-Kv1.4 antibody) and anti-AChR antibody in idiopathic MG with myopathy and myocarditis (6). In the present case, anti-AChR antibody was negative, but anti-titin antibody was positive. Apparently, anti-striated muscle antibody was positive in previously reported cases of anti-PD-1-associated MG (7-9), but the details were not described. To our knowledge, this is the first case of anti-PD-1-associated MG with anti-titin antibody. In idiopathic MG, 80% of patients have anti-AChR antibody, and 10% have anti-MuSK antibody (10). In anti-

**Figure 1.** Pathological features of necrotizing myopathy. A, B: Hematoxylin and Eosin staining demonstrates necrosis and regeneration of muscle fibers and necrotizing myopathy with inflammatory cell infiltration only around necrotic fibers. A: scale bar 100 μm, B: scale bar 50 μm. C: Gomori trichrome staining, D: dihydronicotinamide adenine dinucleotide (NADH) staining. Tubular aggregates can be seen. C, D: scale bar 20 μm. E: Major histocompatibility complex (MHC)-I staining demonstrates light staining of muscle fibers. Scale bar 100 μm. F: Membrane attack complex (MAC) staining demonstrates the deposition of necrotic fibers, with light deposition of non-necrotic fibers. Scale bar 50 μm.
Inclusion of necrotizing myopathy, nonspecific myopathy, and performed. The reported pathological changes have varied, PD-1-associated MG, however, the positive rate for anti-PD-1 monoclonal antibodies is: 

<table>
<thead>
<tr>
<th>Case/age (y)/sex</th>
<th>Cancer</th>
<th>PD-1</th>
<th>Onset</th>
<th>Diplopia/ptosis</th>
<th>AChR/MuSK/titin</th>
<th>CK U/L</th>
<th>Treatment</th>
<th>Outcome</th>
<th>reference number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/65/M</td>
<td>NSCLC</td>
<td>Nivolumab</td>
<td>25 days</td>
<td>+/-</td>
<td>-/-/ND</td>
<td>ND</td>
<td>ChEI</td>
<td>CR</td>
<td>4</td>
</tr>
<tr>
<td>2/81/M</td>
<td>Melanoma</td>
<td>Pembrolizumab</td>
<td>58 days</td>
<td>+/-</td>
<td>-/ND/ND</td>
<td>ND</td>
<td>PRED</td>
<td>CR</td>
<td>5</td>
</tr>
<tr>
<td>3/74/F</td>
<td>Melanoma</td>
<td>Nivolumab</td>
<td>28 days</td>
<td>+/-</td>
<td>4.0/ND/ND</td>
<td>654</td>
<td>ChEI, PRED</td>
<td>PR</td>
<td>3</td>
</tr>
<tr>
<td>4/57/M</td>
<td>NSCLC</td>
<td>Nivolumab</td>
<td>58 days</td>
<td>+/-</td>
<td>0.5/ND/ND</td>
<td>57</td>
<td>ChEI, PRED</td>
<td>MM</td>
<td>3</td>
</tr>
<tr>
<td>5/73/M</td>
<td>NSCLC</td>
<td>Pembrolizumab</td>
<td>23 days</td>
<td>+/-</td>
<td>-/-/7,311</td>
<td>7,311</td>
<td>PRED</td>
<td>CR</td>
<td>present</td>
</tr>
</tbody>
</table>


Figure 2. Clinical course. The patient showed elevation of CK to 600 U/L at 23 days after and 7,311 U/L at 30 days after the administration of pembrolizumab, at which point he became aware of diplopia and ptosis. Various investigations were negative, and myasthenia gravis was diagnosed based on his symptoms that co-existed with myopathy. A left biceps muscle biopsy was performed. The patient received an ascending-dose regimen of prednisolone that increased by 5 mg every 5 days to a total of 20 mg. After steroid therapy, he developed exacerbations of ptosis and diplopia, and extraocular muscle weakness appeared. This was considered initial worsening. The CK level showed a trend toward reduction, but it remained high, so steroid pulse therapy (methylprednisolone 1 g/day 3 times) was given. The CK level then decreased to the normal range, and his symptoms improved. After four months, ptosis disappeared, and extraocular muscle weakness improved.

PD-1-associated MG, however, the positive rate for anti-AChR antibody differs widely, from 20% (9) to 73% (11). Anti-MuSK antibody has never been reported in a case of anti-PD-1-associated MG.

There have been several cases of anti-PD-1 monoclonal antibody-associated myopathy in which a muscle biopsy was performed. The reported pathological changes have varied, including necrotizing myopathy, nonspecific myopathy, and myopathy with complement-mediated microvasculopathy (2, 9). Serum CK is not elevated in all cases, but it is elevated in patients with necrotizing myopathy, as in the present case. This is the first case of anti-PD-1 monoclonal-antibody-associated myopathy that showed tubular aggregates on muscle pathology. Tubular aggregates are found in cases of periodic paralysis, congenital myasthenia, and myopathy due to abnormal store-operated Ca2+ chan-
nels (12), but the present case had neither clinical manifestations nor a family history suggesting any of these conditions. The relationship between tubular aggregates and anti-PD-1 monoclonal antibody therefore remains unclear.

**Conclusion**

We herein report a case of anti-PD-1-associated MG. Unlike other cases with anti-PD-1-associated MG, the present case showed ocular MG without limb or trunk weakness, although the serum CK level was high, and necrotic and regenerating fibers were seen in the muscle. Interestingly, antititin antibody was positive, and tubular aggregates were seen on muscle pathology, although the associations of these findings with PD-1 are still unclear. Similar cases will need to be accumulated in order to better understand this relationship.

The authors state that they have no Conflict of Interest (COI).

**References**


The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).